Skip to content

CLL-Lymphoma

US Focus Meeting 2026


📍 Estancia La Jolla Hotel, 9700 N Torrey Pines Rd, La Jolla, CA 92037

🗓️ May 8 - 9, 2026


Last Year's Highlights

Dear Colleagues and Friends,

We are delighted to extend our warmest invitation to the CLL-Lymphoma Focus Meeting 2026, to be held on May 8 - 9, 2026.  

Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing CLL-Lymphoma research and patient treatment.  

This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.  

 

Chairs of CLL-Lymphoma US Focus Meeting 2026:

SO

Susan O’Brien, MD
University of California, Irvine Medical Center, Los Angeles, CA 


Christopher-Flowers

Christopher Flowers, MD
MD Anderson Cancer Center, Houston, TX


Supporters to be announced...
Interested in supporting this meeting? Get in contact:
neve.rowlands@md-education.com

Agenda & Faculty

May 8, 2026 | CLL Day  

07:00 AM
Registration Opens
08:00 AM
Independent Expert Discussion Supported by AbbVie
08:45 AM
Coffee Break

Session I
Moderated by:

TBD

KOL TBD
KOL TBD

09:00 AM
Proteomics in CLL
Catherine-Wu-1
Catherine Wu, MD
Dana-Farber Cancer Institute, Boston, MA
09:20 AM
How I Choose Frontline Therapy for Which Patient

NJ

Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX
09:40 AM
Where Does Pirtobrutinib Fit in Now?
Mahesh-Swaminathan
Mahesh Swaminathan, MD
MD Anderson Cancer Center, Houston, TX
10:00 AM
Panel Discussion
10:30 AM
Coffee Break

Session II
Moderated by:

TBD

KOL TBD
KOL TBD

10:50 AM
CAR-T in CLL
David-Maloney-1
David Maloney, MD
Fred Hutchinson Cancer Research Center, Seattle, WA
11:10 AM
BTKI + BCL2i Combinations in CLL
Mazyar-Shadman-1
Mazyar Shadman, MD
Fred Hutchinson Cancer Research Center, Seattle, WA
11:30 AM
Survivorship in CLL
Alessandra-Ferrajoli-1
Alessandra Ferrajoli, MD
MD Anderson Cancer Center, Houston, TX
11:50 AM
Panel Discussion
12:20 PM
Industry Supported Independent Expert Discussion Supported by Lilly
01:05 PM
Lunch Break + Faculty and Fellow Photo

Session III
Moderated by:

TBD

KOL TBD
KOL TBD

01:55 PM
Treatment of Patients with P53 Aberrations
Nicole-Lamanna-1
Nicole Lamanna, MD
The Herbert Irving Comprehensive Cancer Center, New York, NY
02:15 PM
Update on Richters
Meghan-Thompson-1
Meghan Thompson, MD
Memorial Sloan Kettering Cancer Center, New York City, NY
02:35 PM
Is the Use of MRD Standard of Care in CLL?
Versha-Banerji
Versha Banerji, MD
Cancer Care Manitoba, Winnipeg, Canada
02:55 PM
Panel Discussion
03:25 PM
Coffee Break
03:45 PM
Industry Supported Independent Expert Discussion

Session IV
Moderated by:

TBD

KOL TBD
KOL TBD

04:30 PM
BTK Degraders
Matthew-Davids-1
Matthew Davids, MD
Dana-Farber Cancer Institute, Boston, MA
04:50 PM
Bispecifics in CLL
Bita-Fakhri
Bita Fakhri, MD
Stanford Medicine, CA
05:10 PM
Future Questions in CLL
Jennifer-Brown-1
Jennifer Brown, MD
Dana-Farber Cancer Institute, Boston, MA
05:30 PM
Panel Discussion
06:00 PM
Adjourn

May 9, 2026 | Lymphoma Day

07:00 AM
Registration Opens
08:00 AM
Industry Supported Independent Expert Discussion
08:45 AM
Coffee Break & Opening Remarks

Session V: Biomarkers, MRD Precision Tools in Lymphoma
Moderated by:

TBD

TBD
TBD

09:05 AM
Cell-Free DNA in Lymphoma: From Detection to Decision-Making
Ash-Alizadeh-1
Ash Alizadeh, MD
Stanford Medicine, CA
09:25 AM
MRD and Risk-Adapted Approaches in LBCL and FL

JG

Jordan S. Goldstein, MD
Stanford Medicine, CA

 

09:45 AM
Genetic Subtype-Guided Trials Clinical Application in 2026
Laura-Hilton
Laura Hilton , MD
BC Cancer Agency, Vancouver, Canada
10:05 AM
Panel Discussion: Genomic-Based Therapy Selection for DLBCL– Are We Ready?
10:35 AM
Coffee Break

Session VI: Frontline and Relapsed LBCL - State of the Art
Moderated by:

TBD

KOL TBD
KOL TBD

10:55 AM
Tailoring First-Line Therapy in LBCL: Pola-R-CHP and Beyond

SR

Sarah Rutherford, MD
Weill Cornell Medicine, New York, NY

 

11:15 AM
Innovative Strategies in Relapsed/ Refractory DLBCL
Dai-Chihara
Dai Chihara, MD
MD Anderson Cancer Center, Houston, TX
11:35 AM
Bispecific Abs in First and Second Line Therapy for DLBCL

EB

Elizabeth Budde, MD
City of Hope Comprehensive Cancer Center, Duarte, CA
11:55 AM
Panel Discussion: Matching Risk to Strategy in DLBCL
12:25 PM
Lunch Break + Faculty and Fellows Photo
01:15 PM
Industry Supported Independent Expert Discussion

Session VII: Clinical Trial Design & Regulatory Innovation
Moderated by:

TBD

KOL TBD
KOL TBD

02:00 PM
Using Real-World Evidence (RWE) in Lymphoma Drug Development
Christopher-Flowers
Christopher Flowers, MD
MD Anderson Cancer Center, Houston, TX

 

02:20 PM
Biomarker Driven Trials: Smarter Endpoints, Learner Designs
Michael-Green
Michael R. Green, PhD
MD Anderson Cancer Center, Houston, TX
02:40 PM
Clinician's View: What Makes a Trial Practically Useful?
Tycel-Phillips
Tycel Phillips, MD
City of Hope, Duarte, CA
03:00 PM
Panel Discussion: Can Trail Design Keep Pace with Discovery?
03:30 PM
Coffee Break
03:50 PM
Industry Supported Independent Expert Discussion

Session VIII: TBD
Moderated by:

Pamela-Allen-1

Pamela Allen, MD
Winship Cancer Institute of Emory University, Georgia

04:35 PM
Novel Targets in PTCL: Clinical Update
Luis-Castillo
Luis Malpica Castillo, MD
MD Anderson Cancer Center, Houston, TX
04:55 PM
Cutaneous T-Cell Lymphoma: Emerging Therapies and Trials
Pamela-Allen-1
Pamela Allen, MD
Winship Cancer Institute of Emory University, Georgia
05:15 PM
CNS Lymphoma: What's New in Targeted Approaches?
Ayushi-Chauhan
Ayushi Chauhan, MD
Wellstar MCG Health, Georgia
05:35 PM
Panel Discussion
06:05 PM
Adjourn

Neve Rowlands
Project Manager

How long has Neve Rowlands been in the business?

Neve Rowlands has been with MD Education since 2023.

About Neve Rowlands

I am a dedicated project manager in the hematology industry, with a current focus on CLL and lymphoma. Specialising in logistical organisation with a sharp eye for detail, and committed to delivering high-quality, seamless events. The most rewarding part of the role is watching meetings come to life. I am passionate about connecting with both familiar and new faces, and driven by the impact of well-executed projects that support meaningful progress in the field.

Neve-Rowlands